KEMOTECH SRL

Their core work

Kemotech is a small Italian chemistry company based in Pula, Sardinia, specializing in applied chemical technology — most likely synthesis, catalysis, and chemical process development. Their participation in OCN4OS points to hands-on competence in organocatalytic nanoparticle systems, meaning they can design or produce catalytic nanomaterials used in organic synthesis reactions. Their third-party role in MOGLYNET — a biomedical project on glycolytic flux and atherosclerosis — suggests they also provide chemical or analytical services to biomedical research consortia. As an SME, they function as a specialized chemistry laboratory or reagent/process provider rather than a large-scale manufacturer.

What they specialise in

How they've shifted over time

Both of Kemotech's recorded H2020 projects launched simultaneously in 2015, so there is no meaningful chronological progression to analyze — the dataset represents a single moment in time rather than an arc of development. What can be said is that in 2015 they were active across two distinct chemistry domains simultaneously: synthetic catalyst design (OCN4OS) and biomedical-adjacent chemistry (MOGLYNET), suggesting they were already positioning themselves as a cross-disciplinary chemistry service provider. No post-2015 H2020 activity is visible, which may reflect a strategic pivot away from EU-funded projects, or simply that their later work falls outside the H2020 dataset.

With no H2020 activity after 2015, the trajectory is unclear — potential partners should verify current activity directly with the company, as their focus may have shifted significantly in the decade since.

How they like to work

Kemotech has never led an H2020 project, consistently joining as a participant or third-party contributor — a pattern typical of specialized SMEs that bring laboratory or technical services to consortia assembled by larger academic or industrial partners. Their 14 unique partners across 9 countries, reached through only two projects, indicates they joined well-connected international networks rather than building a web of repeat collaborators. Working with them likely means engaging a focused technical contributor rather than a project management resource.

Kemotech has reached 14 unique consortium partners across 9 countries through two MSCA projects, suggesting their network is geographically broad despite the small project count. Their MSCA participation connects them primarily to academic institutions and research centers across Europe rather than industrial partners.

What sets them apart

Kemotech occupies an unusual niche as a private-sector chemistry SME embedded in MSCA networks, which are dominated by universities and research institutes — this means they can bridge academic catalyst research and applied industrial chemistry in ways that purely academic partners cannot. Their location in Sardinia, a less-represented Italian region in EU research networks, may make them attractive to consortia seeking geographic diversity. However, with only two recorded projects and no coordinator experience, they are a supporting player rather than a consortium anchor.

Highlights from their portfolio

• OCN4OS
  The only project for which Kemotech received direct EC funding (EUR 189,000), and the clearest signal of their core technical identity — organocatalytic nanoparticle design for organic synthesis within an MSCA-RISE staff exchange network.
• MOGLYNET
  A longer-duration project (2015-2019) in a biomedical domain well outside typical chemistry SME territory, demonstrating Kemotech's willingness to contribute chemical expertise to health-focused consortia as a third party.